Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07195071 · ClinicalTrials.gov registry record · NA
Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening
A NA study of Hereditary Cancer Syndrome, sponsored by Columbia University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT07195071: Recruiting NA study of Hereditary Cancer Syndrome, sponsored by Columbia University.
NCT07195071 is a NA study of Hereditary Cancer Syndrome that is actively recruiting participants, run by Columbia University. The registered enrollment target is 1,000 participants, above the 508-participant average among 4 other Hereditary Cancer Syndrome trials with a reported enrollment target (97% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07195071, a NA study of Hereditary Cancer Syndrome, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the acceptability of hereditary cancer testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention
Primary Outcome
The percent of patients who complete hereditary cancer screening (HCS) when offered in addition to routine obstetrical carrier screening (OCS) during preconception and obstetrical-related care.
Conditions Studied
Interventions
- DEVICE Natera empower comprehensive hereditary cancer panel
- DEVICE Obstetrical carrier screening
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-02-12 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
What NCT07195071 shows while recruiting
NCT07195071 is an interventional study that assigns participants to a tested intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus, above the 508-participant average among 4 other Hereditary Cancer Syndrome trials with a reported enrollment target (97% higher).
The record links to 1 condition, with Hereditary Cancer Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Natera empower comprehensive hereditary cancer panel is the first listed.
NCT07195071 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07195071 about?
NCT07195071 is a clinical study titled "Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening". The investigators hypothesize that preconception and pregnancy may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal care or preconception care. The goal is to evaluate the ac...
What is the current status of trial NCT07195071?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2026-02-12. Estimated completion is 2028-12-31.
What conditions does trial NCT07195071 study?
This clinical trial studies the following conditions: Hereditary Cancer Syndrome.
What interventions are being tested in trial NCT07195071?
The interventions under investigation include: Natera empower comprehensive hereditary cancer panel (DEVICE), Obstetrical carrier screening (DEVICE).
Who is sponsoring clinical trial NCT07195071?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07195071 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Cancer Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment
RECRUITING · NA
-
Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC)
RECRUITING · NA
-
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
RECRUITING
-
Li-Fraumeni & TP53 (LiFT UP): Understanding and Progress
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI